Botulinum toxin treatment of pelvic floor disorders and genital pain in women

Current Women's Health Reviews

Volumn 4, Issue 3, 2008, Pages 180-187

  Bertolasi, Laura ^a   Frasson, Emma ^b   Graziottin, Alessandra ^c  

^a UNIVERSITY OF VERONA   (Italy)

^b Department of Neurology   (Italy)

^c H San Raffaele Resnati   (Italy)

Author keywords

Botulinum toxin type A; Chronic pelvic pain; EMG; Pelvic floor disorders; Urinary dysfunctions; Vaginismus; Vulvar vestibulitis syndrome

Indexed keywords

BOTULINUM TOXIN A; PLACEBO; SODIUM CHLORIDE;

ANALGESIA; CLINICAL TRIAL; CYSTITIS; DRUG EFFICACY; DRUG INDICATION; DYSPAREUNIA; DYSTONIA; ELECTROMYOGRAPHY; EVIDENCE BASED MEDICINE; FEMALE; FLATULENCE; FLU LIKE SYNDROME; GENITAL PAIN; HUMAN; INTERSTITIAL CYSTITIS; LEVATOR ANI MUSCLE; MEDICAL DECISION MAKING; MEDLINE; MYALGIA; PELVIC ORGAN PROLAPSE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEXUAL BEHAVIOR; TREATMENT OUTCOME; URINE INCONTINENCE; VAGINISM; VISUAL ANALOG SCALE; VULVAR VESTIBULITIS; VULVODYNIA;

EID: 53649106529     PISSN: 15734048     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340408785821755     Document Type: Review

References (63)

1. Metts JF. Vulvodynia and vulvar vestibulitis: challenges in diagnosis and management. Am Fam Physician 1999; 59:1 547-56, 1561-2.
2. Reed BD. Vulvodynia: diagnosis and management. Fam Physician 2006; 73: 1231-8.
3. Graziottin A. Sexual pain disorders: dyspareunia and vaginismus In: Porst H. Buvat J. (Fds), ISSM (International Society of Sexual Medicine) Standard Committee Book, Standard practice in Sexual Medicine, Blackwell, Oxford, UK, 2006; 342-350.
4. Graziottin A. Dyspareunia and vaginismus: review of the literature and treatment. Current Sexual Health Reports 2008; 5: 43-50.
5. Ortiz DD. Chronic pelvic pain in women. Am Fam Physician 2008; 77: 1535-42.
6. Mathias SD, Kuppermann M, Liberman RF, Lipschutz RC, Steege JF. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Obstet Gynecol 1996; 7: 321-7.
7. Latthe P, Mignini L, Gray R, Hills R, Khan K. Factors predisposing women to chronic pelvic pain: systematic review. BMJ 2006; 332: 749-55.
8. Breton A, Miller CM, Fisher K. Enhancing the sexual function of women living with chronic pain: A cognitive-behavioural treatment group. Pain Res Manag 2008; 13: 219-24.
9. Rosenbaum TY, Owens A. The role of pelvic floor physical therapy in the treatment of pelvic and genital pain-related sexual dysfunction (CME). J Sex Med 2008; 5: 513-23.
10. Basson R, Leiblum S, Brotto L, et al. Revised definitions of women's sexual dysfunction. J Sex Med 2004; 1: 40-8.
11. Lamont JA. Vaginismus. Am J Obstet Gynecol 1978; 131: 633-636.
12. Jost W. In: Moore P and Naumann M, Ed, Handbook of botulinum toxin treatment. Massachusetts; Blackwell Science 2003; 360-380.
13. Bertolasí L, Frasson E, Bottanelli M, Vicentini S, Didonè G, Graziottin A. Coexisting idiopathic cervical dystonia and primary vaginismus: a case report. J Neurol 2008; 255: 443-5.
14. Brin MF, Vapnek JM. Treatment of vaginismus with botulinum toxin injections. Lancet 1997; 349: 252-3.
15. Shafik A, ElShibai O. Study of the pelvic floor muscles in vaginismus: a concept of pathogenesis. Eur J Obstet Gynecol Reprod Biol 2002; 105: 67-70.
16. Plaut M. Graziottin A. Heaton J. Sexual Dysfunction Fast Facts Series, Health Press, Oxford, UK, 2004.
17. Seo JT, Choe JH, Lee WS, Kim KH. Efficacy of functional electrical stimulation-biofeedback with sexual cognitive-behavioral therapy as treatment of vaginismus. Urology 2005; 66: 77-81.
18. Crowley T, Richardson D, Goldmeier D. Bashh Special Interest Group for Sexual Dysfunction. Recommendations for the management of vaginismus: BASHH Special Interest Group for Sexual Dysfunction. Int J STD AIDS 2006; 17:14-8.
19. van Lankveld JJ, ter Kuile MM, de Groot HE, Melles F, Nefs J, Zandbergen M. Cognitive-behavioral therapy for women with lifelong vaginismus: a randomized waiting-list controlled trial of efficacy. J Consult Clin Psychol 2606; 74: 168-78.
20. Goetsch MF. Vulvar vestibulitis: prevalence and historic features in a general gynecologic practice population. Am J Obstet Gynecol 1991; 164: 1609-16.
21. Pukall CF, Binik YM, Khalifè S, et al. Vestibular tactile and pain thresholds in women with vulvar vestibulitis syndrome. Pain 2002; 96: 163-75.
22. Giesecke J, Reed BD, Haefner HK, et al. Quantitative sensory testing in vulvodynia patients and increased peripheral pressure pain sensitivity. Obstet Gynecol 2004; 104: 126-33.
23. Graziottin A, Castoldi E, Montorsi F, Salonia A, Maga T. Vulvodynia: the challenge of "unexplained" genital pain. J Sex Marital Ther 2001; 27: 503-12.
24. Bachmann GA, Rosen R, Pinn VW, et al. Vulvodynia: a state-of-the-art consensus on definitions, diagnosis and management. J Reprod Med 2006; 51: 447-56
25. Gunter J. Vulvodynia: new thoughts on a devastating condition. Obstet Gynecol Surv 2007; 62: 812-9.
26. Ter Kuile MM, Van Lankveld JJ, Vlieland CV, Willekes C, Weijenborg PT. Vulvar vestibulitis syndrome: an important factor in the evaluation of lifelong vaginismus? J Psychosom Obstet Gynaecol 2005; 26: 245-9.
27. Munday P, Buchan A. Vulval vestibulitis. BMJ 2004; 328: 1214-5.
28. Graziottin A, Brotto L. Vulvar vestibulitis syndrome: clinical approach. J Sex Marital Ther 2004; 30: 125-39.
29. Bornstein J, Goldschmid N, Sabo E. Hyperinnervation and mast cell activation may be used as histopathologic diagnostic criteria for vulvar vestibulitis. Gynecol Obstet Invest 2004; 58: 171-8
30. Halperin R, Zehavi S, Vaknin Z, et al. The major histopathologic characteristics in the vulvar vestibulitis syndrome.1: Gynecol Obstet Invest 2005; 59: 75-9.
31. Graziottin A. Mastcells and their role in bridging chronic inflammation and neuropathic pain. In: Goldstein A, Pukall C, Goldstein I. (Eds), Female Sexual Pain Disorders: Evaluation and Management, Blackwell Publishing 2008 (accepted).
32. Vincenti E. Graziottin A. Sexual pain disorders: management by anesthetic blocks. In: Goldstein I. Meston C. Davis S. Traish A. (Eds), Women's Sexual Function and Dysfunction: Study, Diagnosis and Treatment, Taylor and Francis, London, UK, 2006; 524-528.
33. Rapkin AJ, McDonald JS, Morgan M. Multilevel local anesthetic nerve blockade for the treatment of vulvar vestibulitis syndrome. Am J Obstet Gynecol 2008; 198: 41.
34. Goetsch MF. Surgery combined with muscle therapy for dyspareunia from vulvar vestibulitis: an observational study. J Reprod Med 2007; 52: 597-603.
35. Goldstein AT, Klingman D, Christopher K, Johnson C, Marinoff SC. Surgical treatment of vulvar vestibulitis syndrome: outcome assessment derived from a postoperative questionnaire. J Sex Med 2006; 3: 923-31.
36. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus 1980; 17: 21-5.
37. Dauer WT, Burke RE, Greene P, Fahn S. Current concept on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain 1998; 121: 547-60.
38. Jeynes LC, Gauci CA. Evidence for the use of botulinum toxin in the chronic pain setting-a review of the literature. Pain Pract 2008 May 23.
39. Naumann M, So Y, Argoff CE, Childers, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70: 1707-14.
40. Simpson DM, Blitzer A, Brashear A, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70: 1699-706.
41. Simpson DM, Gracies JM, Graham HK, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum nourotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70:1691-8.
42. Vittal H, Pasricha PF. Botulinum toxin for gastrointestinal disorders: therapy and mechanisms. Neurotox Res 2006; 9: 149-59.
43. Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol 2005; 53: 3-9.
44. Purkiss J, Welch M, Doward S, Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 2000; 59: 1403-6.
45. Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci 2007; 120: 2864-74.
46. Romito S, Bottanelli M, Pellegrini M, Vicentini S, Rizzuto N, Bertolasi L. Botulinum toxin for the treatment of genital pain syndromes. Gynecol Obstet Invest 2004; 58:164-67.
47. Jarvis SK, Abbott JA, Lenart MB, Steensma A, Vancaillie TG. Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol 2004; 44: 46-50.
48. Thomson AJ, Jarvis SK, Lenart M, Abbott JA, Vancaillie TG. The use of botulinum toxin type A (BOTOX) as treatment for intractable chronic pelvic pain associated with spasm of the levator ani muscles. BJOG 2005; 112: 247-9.
49. Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol 2006; 108: 915-23.
50. Shafik A, El-Sibai O. Vaginismus: results of treatment with botulin toxin. J Obstet Gynaecol 2000; 20: 300-2.
51. Ghazizadeh S, Nikzad M. Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol 2004; 104: 922-25.
52. Gunter J, Brewer A, Tawfik O. Botulinum toxin a for vulvodynia: a case report. J Pain 2004; 5: 238-40.
53. Brown CS, Glazer HI, Vogt V, Menkes D, Bachmann G. Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data. J Reprod Med 2006; 51: 635-41.
54. Dykstra DD, Presthus J. Botulinum toxin type A for the treatment of provoked vestibulodynia: an open-label, pilot study. J Reprod Med 2006; 51: 467-70.
55. Yoon H, Chung WS, Shim BS. Botulinum toxin A for the management of vulvodynia. Int J Impot Res 2007; 19: 84-7.
56. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: Author, 2000.
57. Reissing ED, Binik YM, Khalife S. Does vaginismus exist? A critical review of the literature. J Nerv Ment Dis 1999; 187: 261-74.
58. Reissing ED, Binik YM, Khalifé S, et al. Vaginal Spasm, Pain, and Behavior: An Empirical Investigation of the Diagnosis of Vaginismus. Arch Sex Behav 2004; 33: 5-17.
59. Hallan RI, Williams NS, Melling J, Waldron DJ, Womack NR, Morrison JF. Treatment of anismus in intractable constipation with botulinum A toxin. Lancet 1988; 2: 714-7.
60. Maria G, Cadeddu F, Brandara F, Marniga G, Brisinda G. Experience with type A botulinum toxin for treatment of outlet-type constipation. Am J Gastroenterol 2006; 101: 2570-5.
61. Peters KM. Killinger KA. Carrico DJ. Ibrahim IA. Diokno AC. Graziottin A. Sexual function and sexual distress in women with interstitial cystitis: a case control study. Urology 2007; 70: 543-547.
62. Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E. Botulinum A toxin intravesical. injection in patients with painful bladder syndrome: 1-year followup. J Urol 2008; 179: 1031-4.
63. Ramsay AK, Small DR, Conn IG. Intravesical botulinum toxin type A in chronic interstitial cystitis: results of a pilot study. Surgeon 2007; 5: 331-3.